@article {1513168,
	title = {Metabolic labeling and targeted modulation of dendritic cells},
	journal = {Nat Mater},
	volume = {19},
	number = {11},
	year = {2020},
	month = {2020 11},
	pages = {1244-1252},
	abstract = {Targeted immunomodulation of dendritic cells (DCs) in vivo will enable manipulation of T-cell priming and amplification of anticancer immune responses, but a general strategy has been lacking. Here we show that DCs concentrated by a biomaterial can be metabolically labelled with azido groups in situ, which allows for their subsequent tracking and targeted modulation over time. Azido-labelled DCs were detected in lymph nodes for weeks, and could covalently capture dibenzocyclooctyne (DBCO)-bearing antigens and adjuvants via efficient Click chemistry for improved antigen-specific CD8+ T-cell responses and antitumour efficacy. We also show that azido labelling of DCs allowed for in vitro and in vivo conjugation of DBCO-modified cytokines, including DBCO-IL-15/IL-15Rα, to improve priming of antigen-specific CD8+ T cells. This DC labelling and targeted modulation technology provides an unprecedented strategy for manipulating DCs and regulating DC-T-cell interactions in vivo.},
	keywords = {Azides, Cancer Vaccines, Cell Line, Tumor, click chemistry, Dendritic Cells, Humans, Immunomodulation, Immunotherapy, Staining and Labeling},
	issn = {1476-1122},
	doi = {10.1038/s41563-020-0680-1},
	author = {Wang, Hua and Sobral, Miguel C and Zhang, David K Y and Cartwright, Adam N and Li, Aileen Weiwei and Dellacherie, Maxence O and Tringides, Christina M and Koshy, Sandeep T and Wucherpfennig, Kai W and Mooney, David J}
}
